Cardiovascularis biztonságossági vizsgálatok SGLT-2-gátló antidiabetikumokkal 2-es típusú diabetesben

Translated title of the contribution: Clinical trials for evaluating cardiovascular safety of sglt-2-inhibitor drugs in patients with type 2 diabetes

Research output: Contribution to journalArticle

Abstract

SGLT-2-inihibitors are considered as a new class among oral antidiabetic drugs. The first derivatives of this class became available in the last couple of years in Hungary. According to the requirements from regulatory bodies, randomized, controlled clinical trials have been initiated in order to evaluate the cardiovascular safety of nearly all new antidiabetic drugs in patients with type 2 diabetes. Among SGLT-2-inhibitors, only one trial with empagliflozine has been completed so far. Based on the endpoints of the EMPA-REG OUTCOME trial a significant decrease in different cardiovascular events and total mortality was observed in type 2 diabetic patients with elevated cardiovascular risk. The exact pathomechanism of this beneficial effect has not been clearly understood. Currently, the position statements and scientific guidelines clearly describe the place of SGLT-2-inhibitor drugs in the treatment algorithm; the beneficial effect of empagliflozine on cardiovascular events should seriously be considered when making therapeutic decision. Together with the results of ongoing studies with SGLT-2-inhibitors (dapagliflozine: DECLARE, canagliflozine: CANVAS), these data will provide a more robust evidence about the cardiovascular safety of this new class of oral antidiabetic drugs.

Translated title of the contributionClinical trials for evaluating cardiovascular safety of sglt-2-inhibitor drugs in patients with type 2 diabetes
Original languageHungarian
Pages (from-to)93-99
Number of pages7
JournalLege Artis Medicinae
Volume26
Issue number3
Publication statusPublished - 2016

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Clinical trials for evaluating cardiovascular safety of sglt-2-inhibitor drugs in patients with type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this